THU0326 Short and long-term follow-up with adalimumad in refractory uveitis associated to behÇet's disease. multicenter study of 74 patients. (15th June 2017)

• Record Type: Journal Article
• Authors: Domínguez-Casas, L; Calvo-Río, V; Beltrán, E; S-Bursόn, J; Mesquida, M; Adán, A; Hernandez, M; H-Grafella, M; V-Pascual, E; M-Costa, L; Sellas, A; Cordero-Coma, M; Díaz-Llopis, M; Gallego, R; Salom, D; G-Serrano, J; Ortego, N; Herreras, J; G-Aparicio, A; Maíz, O; Blanco, A; Torre, I; Díaz-Valle, D; Pato, E; Aurrecoechea, E; Caracuel, M; Gamero, F; Minguez, E; Carrasco, C; Olive, A; Vázquez, J; R-Moreno, O; Manero, J; Muñoz, S; Gandia, M; Rubio-Romero, E; Toyos-SMiera, F; Lόpez-Longo, F; Nolla, J; Revenga, M; Vegas-Revenga, N; Fernández-Díaz, C; Demetrio-Pablo, R; González-Gay, M; Blanco, R;
• Is Part Of: Annals of the rheumatic diseases. Volume 76(2017)Supplement 2
• Page Start: 326
• Page End: 326
• Publication Date: 2017-06-15
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2017-eular.3577
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Objectives: To evaluate the efficacy of adalimumab (ADA) in short and long term follow-up in refractory uveitis of Behçet's disease (BD) Methods: Multicenter study. Ocular inflammation was evaluated according to "SUN working Group" (Am J Ophthalmol 2005;140:509–516), and the macular thickening with OCT. A comparison was carried out between baseline, and follow-up visits. Results are expressed as mean±SD or median [IQR]. Continuous variables were compared with Wilcoxon test. Results: We studied 74 patients/132 affected eyes (39M/35W); mean age 38.7±11.3. The ocular pattern was panuveitis (n=45), posterior uveitis (n=14), anterior uveitis (n=14) and intermediate uveitis (n=1). Before ADA, systemic treatment with corticosteroids, iv metilprednisolone (n=23), Cyclosporin A (58), azathioprine (33), metotrexate (31) and other drugs (28) was used. The dose of ADA was 40 mg/2 weeks/ sc in monotherapy (n=22) or combined (n=52). Most patients showed a rapid and progressive improvement (TABLE). The 24 patients (37 affected eyes) with CME showed a significant improvement. ADA was optimized in 23 (31.1%) that were in remission for 15.3±9 months. Interval of administration was increased to 3 (n=6), 4 (13), 5 (1), 6 (1) and 8 weeks. After a mean follow-up of 13.0±9.7 months after optimization, 21 patients were stable and 2 had a severe flare. In 4 patients ADA was stopped after 35.2±9.3 months in remission. The main adverse effects observed were lymphoma (n=1), pneumonia (1), and 2° bacteriemia by E. Coli (1) Conclusions: ADA was effective in short and long-term follow-up in refractory uveitis associated to BD. Optimization or even suspension of ADA is possible. Disclosure of Interest: None declared